Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 218

1.

Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs).

Hashim YM, Trinkaus KM, Linehan DC, Strasberg SS, Fields RC, Cao D, Hawkins WG.

Ann Surg. 2014 Feb;259(2):197-203. doi: 10.1097/SLA.0000000000000348.

2.

Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients.

Parekh JR, Wang SC, Bergsland EK, Venook AP, Warren RS, Kim GE, Nakakura EK.

Pancreas. 2012 Aug;41(6):840-4. doi: 10.1097/MPA.0b013e31823cdaa0.

PMID:
22781907
3.

The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer.

Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, Makowiec F.

J Gastrointest Surg. 2009 Jul;13(7):1337-44. doi: 10.1007/s11605-009-0919-2. Epub 2009 May 6.

PMID:
19418101
4.

Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production.

Tsutsumi K, Ohtsuka T, Mori Y, Fujino M, Yasui T, Aishima S, Takahata S, Nakamura M, Ito T, Tanaka M.

J Gastroenterol. 2012 Jun;47(6):678-85. doi: 10.1007/s00535-012-0540-0. Epub 2012 Feb 17.

PMID:
22350698
5.

Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States.

Gratian L, Pura J, Dinan M, Roman S, Reed S, Sosa JA.

Ann Surg Oncol. 2014 Oct;21(11):3515-21. doi: 10.1245/s10434-014-3769-4. Epub 2014 May 20.

6.

Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience.

Wong J, Fulp WJ, Strosberg JR, Kvols LK, Centeno BA, Hodul PJ.

Am J Surg. 2014 Nov;208(5):775-80. doi: 10.1016/j.amjsurg.2014.04.003. Epub 2014 Jun 8.

PMID:
24997491
7.

Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections.

Boninsegna L, Panzuto F, Partelli S, Capelli P, Delle Fave G, Bettini R, Pederzoli P, Scarpa A, Falconi M.

Eur J Cancer. 2012 Jul;48(11):1608-15. doi: 10.1016/j.ejca.2011.10.030. Epub 2011 Nov 28.

PMID:
22129889
8.

Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.

Norton JA, Kivlen M, Li M, Schneider D, Chuter T, Jensen RT.

Arch Surg. 2003 Aug;138(8):859-66.

PMID:
12912744
9.

Surgical experience with nonfunctioning neuroendocrine tumors of the pancreas.

Matthews BD, Heniford BT, Reardon PR, Brunicardi FC, Greene FL.

Am Surg. 2000 Dec;66(12):1116-22; discussion 1122-3.

PMID:
11149582
10.

Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis.

Poultsides GA, Huang LC, Chen Y, Visser BC, Pai RK, Jeffrey RB, Park WG, Chen AM, Kunz PL, Fisher GA, Norton JA.

Ann Surg Oncol. 2012 Jul;19(7):2295-303. doi: 10.1245/s10434-012-2305-7. Epub 2012 Mar 7.

PMID:
22396008
11.

Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors.

Cherenfant J, Stocker SJ, Gage MK, Du H, Thurow TA, Odeleye M, Schimpke SW, Kaul KL, Hall CR, Lamzabi I, Gattuso P, Winchester DJ, Marsh RW, Roggin KK, Bentrem DJ, Baker MS, Prinz RA, Talamonti MS.

Surgery. 2013 Oct;154(4):785-91; discussion 791-3. doi: 10.1016/j.surg.2013.07.004.

PMID:
24074416
12.

Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs).

Partelli S, Gaujoux S, Boninsegna L, Cherif R, Crippa S, Couvelard A, Scarpa A, Ruszniewski P, Sauvanet A, Falconi M.

JAMA Surg. 2013 Oct;148(10):932-9. doi: 10.1001/jamasurg.2013.3376.

PMID:
23986355
13.

Nonfunctional pancreatic neuroendocrine tumors <2 cm on preoperative imaging are associated with a low incidence of nodal metastasis and an excellent overall survival.

Toste PA, Kadera BE, Tatishchev SF, Dawson DW, Clerkin BM, Muthusamy R, Watson R, Tomlinson JS, Hines OJ, Reber HA, Donahue TR.

J Gastrointest Surg. 2013 Dec;17(12):2105-13. doi: 10.1007/s11605-013-2360-9. Epub 2013 Oct 8.

PMID:
24101447
14.

Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy.

Fortner JG, Klimstra DS, Senie RT, Maclean BJ.

Ann Surg. 1996 Feb;223(2):147-53.

15.
16.

Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.

Tsutsumi K, Ohtsuka T, Fujino M, Nakashima H, Aishima S, Ueda J, Takahata S, Nakamura M, Oda Y, Tanaka M.

J Hepatobiliary Pancreat Sci. 2014 Jun;21(6):418-25. doi: 10.1002/jhbp.47. Epub 2013 Oct 20.

PMID:
24142395
17.

Surgery and staging of pancreatic neuroendocrine tumors: a 14-year experience.

Ito H, Abramson M, Ito K, Swanson E, Cho N, Ruan DT, Swanson RS, Whang EE.

J Gastrointest Surg. 2010 May;14(5):891-8. doi: 10.1007/s11605-010-1173-3. Epub 2010 Mar 12.

PMID:
20224984
18.

Resection of pancreatic neuroendocrine tumors: results of 70 cases.

Kazanjian KK, Reber HA, Hines OJ.

Arch Surg. 2006 Aug;141(8):765-9; discussion 769-70.

PMID:
16924083
19.

Comparison of clinicopathologic factors in 122 patients with resected pancreatic and ileal neuroendocrine tumors from a single institution.

Dahdaleh FS, Calva-Cerqueira D, Carr JC, Liao J, Mezhir JJ, O'Dorisio TM, Howe JR.

Ann Surg Oncol. 2012 Mar;19(3):966-72. doi: 10.1245/s10434-011-1997-4. Epub 2011 Aug 16.

PMID:
21845496
20.

Long-term outcome of laparoscopic surgery for pancreatic neuroendocrine tumors.

Haugvik SP, Marangos IP, Røsok BI, Pomianowska E, Gladhaug IP, Mathisen O, Edwin B.

World J Surg. 2013 Mar;37(3):582-90. doi: 10.1007/s00268-012-1893-5.

PMID:
23263686
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk